Phase II Trial of Daily Thalidomide in Extensive Stage Small Cell Lung Cancer Patients Achieving a Complete or Partial Response to Induction Chemotherapy
Latest Information Update: 27 Apr 2010
Price :
$35 *
At a glance
- Drugs Thalidomide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 27 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 09 Mar 2010 Planned end date (1 Nov 2005) added as reported by ClinicalTrials.gov.